💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Cancer care provider to pay U.S. $34.7 million over improper procedure: DOJ

Published 03/08/2016, 02:19 PM
Updated 03/08/2016, 02:30 PM
Cancer care provider to pay U.S. $34.7 million over improper procedure: DOJ

By Suzanne Barlyn

(Reuters) - Cancer care provider 21 Century Oncology Inc has reached a $34.7 million settlement with the U.S. government stemming from the improper use of a procedure that measures the level of radiation that leaves a patient's body after treatment.

The U.S. Department of Justice announced the settlement with Fort Meyers, Florida-based 21 Century Oncology on Tuesday. The company, which has offices in 16 states, performed and billed for procedures that were not medically necessary and in some cases improperly performed, the Justice Department said.

A 21st Center Oncology spokeswoman declined to comment immediately.

Physicians and physicists who performed the procedure, known as "the Gamma function," were not properly trained to interpret or use the results, the Justice Department said.

The oncology company billed Medicaid, a federal healthcare program, for the procedure in cases where physicians did not review results until seven or more days after the patients' final radiation treatments and in cases where no results from the procedure were available due to "technical failures" with equipment, the Justice Department said. OLUSMONEY Reuters US Online Report Money 20160308T172854+0000

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.